Retrotope, Inc.

Isis Innovation Limited

Oxford Gene Technology IP Limited

Biojiva LLC

Mikhail Sergeevich Shchepinov

Edwin M Southern

Dragoslav Vidovic

Peter G Milner

Alan Lewis Hamilton

John Kenneth Elder

John Nicholas Housby

Kalim Mir

Some aspects of the invention provide for a method of treating hepatic disorders, lipidemias and cardiac-related risk factors using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Disorders implicating PUFA oxidation

Methods for preparing isotopically modified 1,4-diene systems from non-isotopically modified 1,4-dienes involve selective oxidation of one or more bis-allylic position(s), or the preparation of isotopically modified 1,4-diene systems via trapping pi-allylic complexes with a source of deuterium or tritium. Such methods are useful for preparing isotopically modified polyunsaturated lipid including polyunsaturated fatty acids and polyunsaturated fatty acid derivatives.

Site-specific isotopic labeling of 1,4-diene systems

Disclosed herein are methods for preparing isotopically modified polyunsaturated lipids containing 1,4-diene systems involving selective isotopic modification of one or more bis-allylic positions of the polyunsaturated lipids in the presence of a transition metal catalyst.

Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD).

Alleviating oxidative stress disorders with PUFA derivatives

Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated arachidonic acid or an ester thereof.

Methods for inhibiting the progression of neurodegenerative diseases

Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.

Methods of treating amyotrophic lateral sclerosis

Disclosed are methods for inhibiting the progression of Amyotrophic Lateral Sclerosis (ALS). The methods include administering to a patient suffering from ALS a composition comprising either deuterated linoleic acid or an ester or deuterated arachidonic acid or an ester thereof.

Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Oxidative retinal diseases

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.

Neurodegenerative disorders and muscle diseases implicating PUFAs

Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopically-modified polyunsaturated fatty acid, an isotopically-modified polyunsaturated fatty acid ester, an isotopically-modified polyunsaturated fatty acid thioester, an isotopically-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopically-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopically-modified polyunsaturated fatty acid and an oxylipin.

Isotopically modified components and therapeutic uses thereof

A nutrient composition comprises an essential nutrient in which at least one exchangeable H atom isH and/or at least one C atom isC. The nutrient is thus protected from, inter alia, active oxygen species.

Growing community of inventors

Kingston Upon Thames, United Kingdom

Mikhail Sergeevich Shchepinov